10:30 AM EDT, 03/16/2026 (MT Newswires) -- Ascendis Pharma ( ASND ) said Monday new data showed children with achondroplasia treated with TransCon CNP kept "consistent" growth improvements through week 104, with improvement in body proportionality during the second year of treatment.

"Two-year data from the ApproaCH Trial demonstrated continued improvement in body proportionality and sustained increases in linear growth," said Ravi Savarirayan, professor at Murdoch Children's Research Institute (Australia).

The data from the once-weekly treatment were shared at the Annual Clinical Genetics Meeting in Baltimore, Maryland.

TransCon CNP was approved by the US Food and Drug Administration under the trade name Yuviwel in February, the firm said, adding that it is expecting a regulatory decision from the European Medicines Agency in Q4.

Price: 229.29, Change: +3.31, Percent Change: +1.46